Florence Bucciarelli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Florence Bucciarelli has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Béatrice Pignolet
Univ Toulouse, Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291 – CNRS UMR5051, Toulouse, France
2 shared publications - Andreas Schulte-Mecklenbeck
Department of Neurology, University of Muenster, Germany; and
1 shared publication - Anke Salmen
Department of Neurology, Center for Clinical Research, St. Josef-Hospital, Ruhr University Bochum
1 shared publication - Antonios Bayas
University of Augsburg
1 shared publication - Bernhard Hemmer
Department of Neurology, School of Medicine and Health, Technical University of Munich, Germany
1 shared publication - Bertram Müller-Myhsok
Statistical Genetics, Max Planck Institute of Psychiatry, Munich, Germany
1 shared publication
Latest Publications
- Open Access
- 6 January 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (1) , 122
Combining Clinical and Genetic Data to Predict Response to Fingolimod Treatment in Relapsing Remitting Multiple Sclerosis Patients: A Precision Medicine Approach
A personalized approach is strongly advocated for treatment selection in Multiple Sclerosis patients due to the high number of available drugs. Machine learning methods proved to be valuable tools in the context of precision medicine. In the present work, we applied machine learning methods to identify a combined clinical and genetic signature of response to fingolimod that could support the prediction of drug response. Two cohorts of fingolimod-treated patients from Italy and France were enrolled and divided into training, validation, and test set. Random forest training and robust feature selection were performed in the first two sets respectively, and the independent test set was used to evaluate model performance. A genetic-only model and a combined clinical–genetic model were obtained. Overall, 381 patients were classified according to the NEDA-3 criterion at 2 years; we identified a genetic model, including 123 SNPs, that was able to predict fingolimod response with an AUROC= 0.65 in the independent test set. When combining clinical data, the model accuracy increased to an AUROC= 0.71. Integrating clinical and genetic data by means of machine learning methods can help in the prediction of response to fingolimod, even though further studies are required to definitely extend this approach to clinical applications
- 6 January 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (1) , 122
Open AccessCombining Clinical and Genetic Data to Predict Response to Fingolimod Treatment in Relapsing Remitting Multiple Sclerosis Patients: A Precision Medicine Approach
A personalized approach is strongly advocated for treatment selection in Multiple Sclerosis patients due to the high number of available drugs. Machine learning methods proved to be valuable tools in the context of precision medicine. In the present work, we applied machine learning methods to identify a combined clinical and genetic signature of response to fingolimod that could support the prediction of drug response. Two cohorts of fingolimod-treated patients from Italy and France were enrolled and divided into training, validation, and test set. Random forest training and robust feature selection were performed in the first two sets respectively, and the independent test set was used to evaluate model performance. A genetic-only model and a combined clinical–genetic model were obtained. Overall, 381 patients were classified according to the NEDA-3 criterion at 2 years; we identified a genetic model, including 123 SNPs, that was able to predict fingolimod response with an AUROC= 0.65 in the independent test set. When combining clinical data, the model accuracy increased to an AUROC= 0.71. Integrating clinical and genetic data by means of machine learning methods can help in the prediction of response to fingolimod, even though further studies are required to definitely extend this approach to clinical applications
- Open Access
Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity
Background: Multiple sclerosis (MS) disease risk is associated with reduced sun exposure. This study assessed the relationship between measures of sun-exposure (vitamin D (vitD), latitude) and MS disease severity, the mechanisms of action, and effect-modification by medication and sun-sensitivity associated MC1R variants. Methods: Two multi-center cohort studies (n NationMS =946, n BIONAT =991). Outcomes were the multiple sclerosis severity score (MSSS) and the number of Gd-enhancing lesion (GELs). RNAseq of four immune cell populations before and after UV-phototherapy of five MS patients. Results: High serum vitD was associated with reduced MSSS ( P NationMS =0.021; P BIONAT =0.007) and reduced risk for disease aggravation ( P NationMS =0.032). Low latitude was associated with higher vitD, lower MSSS ( P NationMS =0.018), fewer GELs ( P NationMS =0.030) and reduced risk for aggravation ( P NationMS =0.044). The influence of latitude on disability seemed to be lacking in the subgroup of interferon-β treated patients (interaction- P BIONAT =0.042, interaction- P NationMS =0.053). In genetic analyses, for carriers of MC1R :rs1805008(T), who reported increased sensitivity towards sunlight ( P NationMS =0.038), the relationship between latitude und the number of GELs was inversed ( P NationMS =0.001). Phototherapy induced a vitD and type I interferon signature that was most apparent in the transcriptome of monocytes ( P =1×10 −6 ). Conclusion: VitD is associated with reduced MS severity and disease aggravation. This is likely driven by sun-exposure, as latitude also correlated with disability and serum vitD. However, sun-exposure might be detrimental for sun-sensitive patients. A direct induction of type I interferons through sun-exposure could explain a reduced effect of latitude in interferon-β treated patients. This could also explain opposite effects of sun-exposure in MS and the type I interferon and sun-sensitivity-associated disease Lupus.
Open AccessSunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity
Background: Multiple sclerosis (MS) disease risk is associated with reduced sun exposure. This study assessed the relationship between measures of sun-exposure (vitamin D (vitD), latitude) and MS disease severity, the mechanisms of action, and effect-modification by medication and sun-sensitivity associated MC1R variants. Methods: Two multi-center cohort studies (n NationMS =946, n BIONAT =991). Outcomes were the multiple sclerosis severity score (MSSS) and the number of Gd-enhancing lesion (GELs). RNAseq of four immune cell populations before and after UV-phototherapy of five MS patients. Results: High serum vitD was associated with reduced MSSS ( P NationMS =0.021; P BIONAT =0.007) and reduced risk for disease aggravation ( P NationMS =0.032). Low latitude was associated with higher vitD, lower MSSS ( P NationMS =0.018), fewer GELs ( P NationMS =0.030) and reduced risk for aggravation ( P NationMS =0.044). The influence of latitude on disability seemed to be lacking in the subgroup of interferon-β treated patients (interaction- P BIONAT =0.042, interaction- P NationMS =0.053). In genetic analyses, for carriers of MC1R :rs1805008(T), who reported increased sensitivity towards sunlight ( P NationMS =0.038), the relationship between latitude und the number of GELs was inversed ( P NationMS =0.001). Phototherapy induced a vitD and type I interferon signature that was most apparent in the transcriptome of monocytes ( P =1×10 −6 ). Conclusion: VitD is associated with reduced MS severity and disease aggravation. This is likely driven by sun-exposure, as latitude also correlated with disability and serum vitD. However, sun-exposure might be detrimental for sun-sensitive patients. A direct induction of type I interferons through sun-exposure could explain a reduced effect of latitude in interferon-β treated patients. This could also explain opposite effects of sun-exposure in MS and the type I interferon and sun-sensitivity-associated disease Lupus.